Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Ani Pharmaceuticals (ANIP) over the last 17 years, with Q3 2025 value amounting to $6.1 million.

  • Ani Pharmaceuticals' Capital Expenditures rose 2682.88% to $6.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.0 million, marking a year-over-year decrease of 704.67%. This contributed to the annual value of $16.2 million for FY2024, which is 8308.53% up from last year.
  • Ani Pharmaceuticals' Capital Expenditures amounted to $6.1 million in Q3 2025, which was up 2682.88% from $4.0 million recorded in Q2 2025.
  • Ani Pharmaceuticals' 5-year Capital Expenditures high stood at $6.1 million for Q3 2025, and its period low was $356000.0 during Q4 2021.
  • Over the past 5 years, Ani Pharmaceuticals' median Capital Expenditures value was $2.4 million (recorded in 2024), while the average stood at $2.6 million.
  • Per our database at Business Quant, Ani Pharmaceuticals' Capital Expenditures tumbled by 8312.8% in 2021 and then surged by 78146.07% in 2022.
  • Ani Pharmaceuticals' Capital Expenditures (Quarter) stood at $356000.0 in 2021, then surged by 781.46% to $3.1 million in 2022, then decreased by 27.37% to $2.3 million in 2023, then increased by 5.05% to $2.4 million in 2024, then skyrocketed by 154.93% to $6.1 million in 2025.
  • Its Capital Expenditures was $6.1 million in Q3 2025, compared to $4.0 million in Q2 2025 and $2.5 million in Q1 2025.